An observational study in Pulmonary Embolism (Diagnosis), sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-01-03.
Sponsored by Assiut University · Observational
Among 18 studies in Pulmonary Embolism by Assiut University — 6 open to participants now, 7 under way, none of them phase 3. Pulmonary Embolism · Assiut University.
Among the 18 studies in Pulmonary Embolism by Assiut University, this one has the largest planned enrollment of the 11 observational ones, is one of 3 that started in 2025, is one of 2 of another kind, and was the 14th registered.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
This study's planned enrollment of 300 is below the median of 361 across 366 observational studies indexed under Pulmonary Embolism.
Browse Pulmonary Embolism studies →6 of the 18 studies in Pulmonary Embolism by Assiut University are open now, in 1 country. Each count lists the studies.
Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →18 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2025.
Median enrollment 68 across the 7 interventional studies, 70 across the 11 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Pulmonary Embolism by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06756373Assiut UniversityMangement of Pulmonary Emboli | 2026-12-17 |
| NCT07728448Assiut UniversityPredictors of Pulmonary Embolism in Interstitial Lung Disease With Worsening Symptoms | 2027-08 |
| NCT07107347Assiut UniversityAssessment of Right Ventricular Function After Acute Pulmonary Embolism: a Comparison of Speckle Tracking Strain and Conventional Echocardiographic Parameters | 2027-09 |
Among the 18 studies in Pulmonary Embolism by Assiut University, from their registry updates:
To assess to which extent we are adherent to ESC guidelines 2019 in management of patients presented with acute pulmonary embolism
Pulmonary embolism (PE) is the third most frequent cardiovascular disease and is associated with a high mortality burden PE is defined as the obstruction of a pulmonary artery, mostly resulting from the dislodgement of thrombotic material from the lower limbs. It has a wide variety of presentations, ranging from an asymptomatic incidental finding to circulatory collapse and sudden death Pulmonary embolism response teams (PERTs) have emerged as a multidisciplinary team for managing acute pulmonary embolism, with a rapid activation process for multimodality assessment, risk stratification and best management especially for complex challenge cases. PERTs help in improving time to PE diagnosis; shorter time to initiation of anticoagulation reducing hospital length of stay, increasing use of advanced therapies as catheter directed therapies without an increase in bleeding complications with decreasing mortality
treatment of patient with pulmonary embolism according to ECS Guidlines
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Comparing ESC 2019 criteria for risk stratification and mortality with new scores \[BOVA , modified FAST, PEITHO-3 models \& POPE\]. -Comparing management and outcomes of in hospital and 30 days follow up of pulmonary embolism before and after starting PERT in our center
mortality rate
mortality rate of pulmonary embolism
Time frame: 30 day
No study locations are listed for this record.
Plan to share: No
This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.